Tg Therapeutics Stock Buy Hold or Sell Recommendation
| TGTX Stock | USD 34.80 0.20 0.57% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding TG Therapeutics is 'Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell TG Therapeutics given historical horizon and risk tolerance towards TG Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for TG Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out TG Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide. In addition, we conduct extensive research on individual companies such as TGTX and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
TGTX |
Execute TG Therapeutics Buy or Sell Advice
The TGTX recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on TG Therapeutics. Macroaxis does not own or have any residual interests in TG Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute TG Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Good | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
TG Therapeutics Trading Alerts and Improvement Suggestions
| TG Therapeutics appears to be risky and price may revert if volatility continues | |
| TG Therapeutics currently holds about 195.71 M in cash with (31.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| TG Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: TG Therapeutics to Participate in the Evercore HealthCONx Conference |
TG Therapeutics Returns Distribution Density
The distribution of TG Therapeutics' historical returns is an attempt to chart the uncertainty of TG Therapeutics' future price movements. The chart of the probability distribution of TG Therapeutics daily returns describes the distribution of returns around its average expected value. We use TG Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of TG Therapeutics returns is essential to provide solid investment advice for TG Therapeutics.
| Mean Return | 0.69 | Value At Risk | -4.62 | Potential Upside | 7.62 | Standard Deviation | 4.10 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of TG Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
TGTX Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as TG Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading TG Therapeutics back and forth among themselves.
| Shares | Sofinnova Ventures | 2024-06-30 | 1.9 M | Deep Track Capital, Lp | 2024-09-30 | 1.7 M | Nuveen Asset Management, Llc | 2024-06-30 | 1.7 M | Hood River Capital Management Llc | 2024-09-30 | 1.6 M | Millennium Management Llc | 2024-06-30 | 1.5 M | Woodline Partners Lp | 2024-06-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.2 M | Fmr Inc | 2024-09-30 | 1.2 M | Vanguard Group Inc | 2024-09-30 | 15.4 M | Blackrock Inc | 2024-06-30 | 11.4 M |
TG Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 70.7M | 440.8M | (254.5M) | (196.6M) | (9.4M) | (8.9M) | |
| Free Cash Flow | (132.9M) | (214.9M) | (296.0M) | (176.2M) | (31.4M) | (33.0M) | |
| Other Non Cash Items | 3.5M | 4.0M | 2.4M | 4.1M | 128.8M | 135.3M | |
| Capital Expenditures | 2.2K | 90K | 131K | 357K | 401K | 14K | |
| Net Income | (172.9M) | (279.4M) | (348.1M) | (198.3M) | 12.7M | 13.3M | |
| End Period Cash Flow | 113.9M | 554.7M | 300.2M | 103.6M | 92.9M | 59.5M | |
| Depreciation | 282K | 374K | 494K | 515K | 423K | 444.2K | |
| Change To Netincome | 11.5M | 81.0M | 60.7M | 19.1M | 21.9M | 23.0M | |
| Net Borrowings | 29.2M | 40M | 39.0M | (975K) | (1.1M) | (1.1M) | |
| Investments | (718K) | (24.5M) | 69K | (20.0M) | (50.7M) | (48.1M) | |
| Change Receivables | (11K) | (6K) | (1.4M) | 1.4M | 1.6M | 1.7M |
TG Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to TG Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that TG Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a TGTX stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.42 | |
β | Beta against Dow Jones | 2.03 | |
σ | Overall volatility | 4.15 | |
Ir | Information ratio | 0.13 |
TG Therapeutics Volatility Alert
TG Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure TG Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact TG Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.TG Therapeutics Fundamentals Vs Peers
Comparing TG Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze TG Therapeutics' direct or indirect competition across all of the common fundamentals between TG Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as TG Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of TG Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare TG Therapeutics to competition |
| Fundamentals | TG Therapeutics | Peer Average |
| Return On Equity | -0.0805 | -0.31 |
| Return On Asset | -7.0E-4 | -0.14 |
| Profit Margin | (0.05) % | (1.27) % |
| Operating Margin | 0.15 % | (5.51) % |
| Current Valuation | 5.36 B | 16.62 B |
| Shares Outstanding | 155.66 M | 571.82 M |
| Shares Owned By Insiders | 9.50 % | 10.09 % |
| Shares Owned By Institutions | 66.41 % | 39.21 % |
| Number Of Shares Shorted | 28.33 M | 4.71 M |
| Price To Earning | (4.14) X | 28.72 X |
| Price To Book | 28.35 X | 9.51 X |
| Price To Sales | 20.46 X | 11.42 X |
| Revenue | 233.66 M | 9.43 B |
| Gross Profit | 2.52 M | 27.38 B |
| EBITDA | 21.06 M | 3.9 B |
| Net Income | 12.67 M | 570.98 M |
| Cash And Equivalents | 195.71 M | 2.7 B |
| Cash Per Share | 1.45 X | 5.01 X |
| Total Debt | 110.8 M | 5.32 B |
| Debt To Equity | 0.62 % | 48.70 % |
| Current Ratio | 4.68 X | 2.16 X |
| Book Value Per Share | 1.34 X | 1.93 K |
| Cash Flow From Operations | (31.41 M) | 971.22 M |
| Short Ratio | 7.32 X | 4.00 X |
| Earnings Per Share | (0.10) X | 3.12 X |
| Target Price | 38.67 | |
| Number Of Employees | 319 | 18.84 K |
| Beta | 2.19 | -0.15 |
| Market Capitalization | 5.42 B | 19.03 B |
| Total Asset | 329.59 M | 29.47 B |
| Retained Earnings | (1.51 B) | 9.33 B |
| Working Capital | 264.22 M | 1.48 B |
| Current Asset | 71.33 M | 9.34 B |
Note: Disposition of 5000 shares by Charney Laurence N of TG Therapeutics subject to Rule 16b-3 [view details]
TG Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as TGTX . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 37745.19 | |||
| Daily Balance Of Power | (0.19) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 35.25 | |||
| Day Typical Price | 35.1 | |||
| Price Action Indicator | (0.55) | |||
| Period Momentum Indicator | (0.20) | |||
| Relative Strength Index | 70.33 |
About TG Therapeutics Buy or Sell Advice
When is the right time to buy or sell TG Therapeutics? Buying financial instruments such as TGTX Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having TG Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.